Achieve Life Sciences (ACHV) is developing cytisinicline, a novel nicotine cessation drug showing superior efficacy to existing treatments in Phase 3 trials, with potential to capture significant market share from 49.2 million US nicotine addicts. Key risks include FDA manufacturing delays with expected Complete Response Letter (CRL), potential 6-month launch delay, and execution risk on commercialization.